Hansoh Pharmaceutical Group Company Limited
3692
Peringkat dalam Saham
#915
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Harga Saham
$4.35
Kapitalisasi Pasar
$26.37B
Perubahan (1 hari)
-1.11%
Perubahan (1 tahun)
-5.84%
Negara
CN
Perdagangan Hansoh Pharmaceutical Group Company Limited (3692)
Kategori
Healthcare
Rasio P/B untuk Hansoh Pharmaceutical Group Company Limited (3692)
Rasio P/B per October 2026 TTM: 4.30
Menurut laporan keuangan dan harga saham terbaru dari Hansoh Pharmaceutical Group Company Limited, rasio P/B saat ini (TTM) adalah 4.30. Pada akhir 2023, rasio P/B perusahaan adalah 3.47.
Riwayat rasio P/B untuk Hansoh Pharmaceutical Group Company Limited dari 2016 hingga 2026
Rasio P/B pada akhir setiap tahun
| Tahun | Rasio P/B | Mengubah |
|---|---|---|
| 2026 (TTM) | 4.30 | 28.00% |
| 2024 | 3.36 | -3.35% |
| 2023 | 3.47 | 1.44% |
| 2022 | 3.42 | -25.17% |
| 2021 | 4.57 | -56.01% |
| 2020 | 10.40 | 7.03% |
| 2019 | 9.72 | -86.95% |
| 2018 | 74.45 | 213.64% |
| 2017 | 23.74 | -55.98% |
| 2016 | 53.92 | 0.00% |
Rasio P/B untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/B | Perbedaan Rasio P/B | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 17.21% |
IN
|
